New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
05:38 EDTACT, FRXActavis expected to seek more deals, WSJ reports
Actavis's (ACT) move to pay $25B for Forest Labs (FRX) shows the company continues to have a strong desire for takeovers, reports the Wall Street Journal. A key consideration, sources say, was its desire to absorb more players in the fragmented generic- and specialty-pharmaceuticals industries. Actavis is paying for Forest with cash and stock in part to keep its leverage ratios low enough so that the newly merged company has the firepower to make additional acquisitions as soon as the deal closes in the next three-to-four months, sources added. Reference Link
News For ACT;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
07:12 EDTACTAmerican Congress of Obstetrics and Gynecology
2015 ACOG Annual Clinical & Scientific Meeting is being held in San Francisco on May 2-6.
April 28, 2015
17:00 EDTACTActavis, Medicines360 announce publication of ACCESS IUS study of LILETTA
Actavis and Medicines360, a nonprofit women's health pharmaceutical company, announced that the initial results of ACCESS IUS, or A Comprehensive Contraceptive Efficacy and Safety Study of an IUS, were published online today in the medical journal Contraception. The study found that LILETTA, or levonorgestrel-releasing intrauterine system, 52 mg, is 99.45% effective for the prevention of pregnancy for up to three years of use in women aged 16-35 regardless of race, parity, or body mass index. The ACCESS IUS trial is still ongoing and will evaluate the efficacy and safety of LILETTA for up to seven years of use.
10:19 EDTACTPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
April 24, 2015
09:27 EDTACTActavis' Dalvance shows positive Phase 3 results for skin infections
Actavis announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of Dalvance with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus. Preliminary top-line data demonstrated the 1500 mg single-dose of Dalvance achieved its primary endpoint of non-inferiority to the two-dose regimen at 48-72 hours after initiation of therapy. Actavis plans to file a supplemental New Drug Application with these data in Q3.
07:09 EDTACTCipher Pharmaceuticals announces Markman hearing in Absorica patent suit
Subscribe for More Information
April 23, 2015
08:16 EDTACTActavis launches Avycaz anti-infective in U.S.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use